DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine (Q44008805)

28 November 2017

title

DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine (English)

1 reference

28 November 2017

Thien Nguyen

6

1 reference

ORCID Public Data File 2021

author name string

Christine Klinguer-Hamour

1

1 reference

28 November 2017

Christine Libon

2

1 reference

28 November 2017

Hélène Plotnicky-Gilquin

3

1 reference

28 November 2017

Marie Claire Bussat

4

1 reference

28 November 2017

Lydie Revy

5

1 reference

28 November 2017

Jean Yves Bonnefoy

7

1 reference

28 November 2017

Nathalie Corvaïa

8

1 reference

28 November 2017

Alain Beck

9

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

28 November 2017

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

28 November 2017

volume

20

1 reference

28 November 2017

issue

21-22

1 reference

28 November 2017

page(s)

2743-2751

1 reference

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Distinct types of lung disease caused by functional subsets of antiviral T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Synthesis and characterization of Respiratory Syncytial Virus protein G related peptides containing two disulfide bridges

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

DDA as an immunological adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Single-dose antenatal tetanus immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

The complete genome sequence of Escherichia coli K-12

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Residual DNA quantification in clinical batches of BBG2Na, a recombinant subunit vaccine against human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Preparation and characterization of large dioctadecyldimethylammonium chloride liposomes and comparison with small sonicated vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Duration of hospitalization in previously well infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

Adjuvants: current status, clinical perspectives and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900193-7

7 January 2021

10.1016/S0264-410X(02)00193-7

Identifiers

DOI

1 reference

28 November 2017

1 reference